EP Patent

EP4724053A1 — Pharmaceutical oral solid dosage forms including liothyronine and levothyroxine salts and methods of making and using the same

Assigned to Genus Lifesciences Inc · Expires 2026-04-15 · 0y expired

What this patent protects

Pharmaceutical oral solid dosage forms including liothyronine and levothyroxine salts and methods of making and using the pharmaceutical oral solid dosage forms are disclosed.

USPTO Abstract

Pharmaceutical oral solid dosage forms including liothyronine and levothyroxine salts and methods of making and using the pharmaceutical oral solid dosage forms are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
EP4724053A1
Jurisdiction
EP
Classification
—
Expires
2026-04-15
Drug substance claim
No
Drug product claim
No
Assignee
Genus Lifesciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.